Efficacy of mebeverin in treatment of abdominal pain

An original study evaluating the effectiveness and safety of mebeverin in treatment of abdominal pain in patients with irritable bowel syndrome (IBS) are presented. Materials and methods: 40 patients diagnosed with IBS, according to the Rome Criteria IV, were monitored. Patients depending on the type of therapy were divided into two groups: 20 patients of the first group had recommendations for lifestyle modification, a hypocaloric diet and took mebeverin per os at a dose of 135 mg three times a day 20 minutes before meals for a month; 20 patients of the second group received only recommendations for lifestyle modification and a hypocaloric diet. All patients were evaluated before and after treatment using the Gastrointestinal Symptom Rating Scale (GSRS), Visual-Analog Pain Intensity Rating Scale (0–10 points), SF‑36 Quality of Life Assessment Question, adverse events assessment. Colonoscopy was performed before treatment to exclude organic pathology of the colon. Results. After treatment patients in the first group had a faster and more significant relief of complaints compared to the second group, a significant improvement in the quality of life on the scales of physical and mental functioning, as well as almost complete disappearance of pain on a visual-analog scale (7.1 out of 10 points before treatment and 0.4 points after). Conclusions. Mebeverin in a dosage of 135 mg three times a day during a month contributes to a significant improvement in well-being, optimizes the quality of life of this category of patients, is effective and safe, which allows us to recommend its use as a first-line spasmolytic drug in the complex therapy of IBS, as well as in various variants of visceral abdominal pain.

1. Ивашкин В. Т. и соавт. Клинические рекомендации Российской гастроэнтерологической ассоциации по ведению пациентов с абдоминальной болью. РЖГГК. 2015. № 4. С. 71–80.

2. Белоусова Е. А. Абдоминальная боль в практике терапевта. // Врач. 2002. № 2. С. 16–20.

3. Яковенко Э. П. Абдоминальный болевой синдром: этиология, патогенез и вопросы терапии. Лечащий врач. № 05–06/01.

4. Brian E. Lacy, Fermín Mearin, Lin Chang, William D. Chey, Anthony J. Lembo, Magnus Simren, Robin Spiller Bowel Disorders. Gastroenterology 2016; 150: 1393–1407.

5. Boisson J, Coudert Ph, Dupuis J, Laverdant Ch, Toulet J. Tolerance de la mebeverine a long terme. Act Ther 1987; 16: 289–92.

6. Опросник GSRS (русскоязычная версия, созданная и рекомендованная МЦИКЖ) [электронный ресурс]. URL: https://medlec.org/lek‑194496.html (дата обращения 07.08.2020).

7. Недошивин А. О., Кутузова А. Э., Петрова Н. Н. и др. Исследование качества жизни и психологического статуса больных с хронической сердечной недостаточностью. // Сердечная недостаточность. 2000; 1 (4): 1–7.

8. Новик А. А., Ионова Т. И., Кайдн П. Концепция исследования качества жизни в медицине. СПб: ЭЛБИ, 1999; 140 с.

9. Ware J. The status of health assessment 1994. / Public Health. 1995; 16: 327–54. DOI: 10.1146/annurev.pu.16.050195.001551.

10. Ware J., Sherbourne C. The Mos SF‑36 item short form health survey (SF‑36): I. Conceptual framework and item selection. // Med. Care. 1992; 30: 473–83.

11. Medic. Studio: изучение и диагностика [электронный ресурс]. URL: https://medic.studio/palliativnaya-meditsina/izuchenie-diagnostika‑65793.html (дата обращения 07.08.2020).